Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study-Reference-Cited by-同舟云学术

Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study

Published:2024-01-19 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Hunt Hannah L.,Goncalves Beatriz G.,Biggs Mary A.,Rico Mia I.,Murray Molly E.,Lebedenko Charlotta G.,Banerjee Ipsita A.^ORCID

Funder

Henry Luce Foundation

NSF-MRI

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11030-023-10772-x.pdf

Reference131 articles.

1. Vagace JM, Gervasini G (2011) Chemotherapy Toxicity in Patients with Acute Leukemia. In: Antica M (Eds), Acute Leukemia - The Scientist’s Perspective and Challenge. Intech Open. doi:https://doi.org/10.5772/841.

2. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–723. https://doi.org/10.1016/j.cell.2017.01.017

3. Alfarouk KO, Stock C-M, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C (2015) Resistance to cancer chemotherapy: failure in drug response from ADME to P-GP. Cancer Cell Int. https://doi.org/10.1186/s12935-015-0221-1

4. Zhu X, Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X (2016) Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther 10:1885–1895. https://doi.org/10.2147/DDDT.S106412

5. Ma Y, Yu S, Ni S, Zhang B, Kung ACF, Gao J, Lu A, Zhang G (2021) Targeting strategies for enhancing paclitaxel specificity in chemotherapy. Front Cell Dev Biol. https://doi.org/10.3389/fcell.2021.626910